11.01.2019 • News

Ineos Oxide Closes Wilmar Purchase

Ineos Oxide Closes Wilmar Purchase (c) Ineos
Ineos Oxide Closes Wilmar Purchase (c) Ineos

In its first acquisition of 2019, Ineos Oxide has completed the purchase of Wilmar’s ethoxylation plant in Lavéra, France.

Graham Beesley, Ineos Oxide’s CEO, commented: “This acquisition comes at an opportune moment for Ineos’s Lavéra ethylene oxide (EO) activities following the recent decision to invest in the Lavéra site.”

The company said last September it planned to spend €200 million on upgrading its European EO plants to meet increased demand, of which €50 million was to be spent at Lavéra in southern France with €150 million going to expand production and storage at Zwijndrecht in Belgium. Ineos expects EO capacity at Lavéra to ultimately reach 270,000 t/y.

Nathalie Haeberli, business manager alkoxylation, added that Ineos Oxide now operates alkoxylation assets on three integrated sites. She said: “We look forward to adding this capacity to our network, that together with our upcoming expansion in Zwijndrecht, Antwerp, Belgium, increases our offering to the European market.”

The acquisition includes the site’s production infrastructure and employees, but Wilmar's commercial portfolio is excluded from the deal.

As part of the transaction, Ineos and Wilmar Europe Trading have entered into a toll manufacturing agreement, which guarantees Wilmar a long-term supply of surfactants from Ineos’s European network.

Wilmar said it now has access to five locations for ethoxylation in northwestern and southern Europe and will continue expanding its activities in European surfactants markets around its natural fatty alcohol plant which it owns and operates in Rozenburg, the Netherlands.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read